Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.

Schuster S, Nadjar A, Guo JT, Li Q, Ittrich C, Hengerer B, Bezard E.

J Neurosci. 2008 Apr 23;28(17):4311-6. doi: 10.1523/JNEUROSCI.4720-07.2008.

2.

Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.

Wang T, Cao X, Zhang T, Shi Q, Chen Z, Tang B.

Neurol Sci. 2015 Aug;36(8):1397-402. doi: 10.1007/s10072-015-2127-z.

PMID:
25787808
3.

The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.

Yin LL, Geng XC, Zhu XZ.

Brain Res Bull. 2011 Nov 25;86(5-6):367-72. doi: 10.1016/j.brainresbull.2011.09.016.

PMID:
21963945
4.

Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.

Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T.

Neurobiol Dis. 2006 Jun;22(3):586-98.

PMID:
16531050
5.

Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.

Schuster S, Doudnikoff E, Rylander D, Berthet A, Aubert I, Ittrich C, Bloch B, Cenci MA, Surmeier DJ, Hengerer B, Bezard E.

Biol Psychiatry. 2009 Mar 15;65(6):518-26. doi: 10.1016/j.biopsych.2008.09.008.

PMID:
18947822
6.

RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.

Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, Nadjar A, Qin C, LaHoste GJ, Li Q, Bioulac BH, Waugh JL, Gurevich E, Neve RL, Bezard E.

J Neurosci. 2007 Dec 26;27(52):14338-48.

7.

L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.

Rangel-Barajas C, Silva I, Lopéz-Santiago LM, Aceves J, Erlij D, Florán B.

Neurobiol Dis. 2011 Jan;41(1):51-61. doi: 10.1016/j.nbd.2010.08.018.

PMID:
20736067
8.
9.

Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.

Lebel M, Chagniel L, Bureau G, Cyr M.

Neurobiol Dis. 2010 Apr;38(1):59-67. doi: 10.1016/j.nbd.2009.12.027.

PMID:
20060905
10.
11.

Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia.

Guigoni C, Bezard E.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S64-7. doi: 10.1016/S1353-8020(09)70783-7. Review.

PMID:
20083011
12.

Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.

Papathanou M, van der Laan R, Jenner P, Rose S, McCreary AC.

Mov Disord. 2013 Jul;28(8):1072-9. doi: 10.1002/mds.25218.

PMID:
23125107
13.

The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.

Eskow KL, Gupta V, Alam S, Park JY, Bishop C.

Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):306-14.

PMID:
17553556
14.

High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease.

Oueslati A, Sgambato-Faure V, Melon C, Kachidian P, Gubellini P, Amri M, Kerkerian-Le Goff L, Salin P.

J Neurosci. 2007 Feb 28;27(9):2377-86.

15.

TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.

Ikeda K, Yoshikawa S, Kurokawa T, Yuzawa N, Nakao K, Mochizuki H.

Eur J Pharmacol. 2009 Oct 12;620(1-3):42-8. doi: 10.1016/j.ejphar.2009.08.013.

PMID:
19686730
16.

Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy).

Stefanova N, Lundblad M, Tison F, Poewe W, Cenci MA, Wenning GK.

Neurobiol Dis. 2004 Apr;15(3):630-9.

PMID:
15056471
17.

Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.

Lane EL, Vercammen L, Cenci MA, Brundin P.

Exp Neurol. 2009 Sep;219(1):355-8. doi: 10.1016/j.expneurol.2009.04.010.

PMID:
19393238
18.

Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.

Fulceri F, Biagioni F, Ferrucci M, Lazzeri G, Bartalucci A, Galli V, Ruggieri S, Paparelli A, Fornai F.

Brain Res. 2007 Mar 2;1135(1):219-29.

PMID:
17222394
19.

Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease.

Bordia T, Campos C, Huang L, Quik M.

J Pharmacol Exp Ther. 2008 Oct;327(1):239-47. doi: 10.1124/jpet.108.140897.

20.

Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias.

Malmlöf T, Rylander D, Alken RG, Schneider F, Svensson TH, Cenci MA, Schilström B.

Exp Neurol. 2010 Oct;225(2):408-15. doi: 10.1016/j.expneurol.2010.07.018.

PMID:
20659451

Supplemental Content

Support Center